IMMUTEP ADR |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.69 USD | +3.46% |
|
+3.46% | +12.08% |
| Sales 2024 * | 4.14M 2.73M 217M | Sales 2025 * | 17.82M 11.73M 935M | Capitalization | 499M 329M 26.18B |
|---|---|---|---|---|---|
| Net income 2024 * | -44M -28.96M -2.31B | Net income 2025 * | -42M -27.64M -2.2B | EV / Sales 2024 * | 102 x |
| Net cash position 2024 * | 75.11M 49.44M 3.94B | Net cash position 2025 * | 61.67M 40.59M 3.23B | EV / Sales 2025 * | 24.6 x |
| P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
-11.7
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.19% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.46% | ||
| 1 week | +3.46% | ||
| 1 month | +5.91% | ||
| 3 months | +27.49% | ||
| 6 months | +44.62% | ||
| Current year | +12.08% |
1 week
2.56
2.80
1 month
2.113.05
Current year
2.083.05
1 year
1.503.90
3 years
1.475.44
5 years
0.537.95
10 years
0.5321.60
| Managers | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 31/12/10 |
David Fang
DFI | Director of Finance/CFO | - | 28/02/18 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 07/05/13 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 31/12/10 |
Anne Anderson
BRD | Director/Board Member | - | 02-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 2.69 | +3.46% | 168,591 |
| 01/05/24 | 2.6 | -3.35% | 212,200 |
| 30/04/24 | 2.69 | +0.75% | 254,566 |
| 29/04/24 | 2.67 | +0.75% | 612,450 |
| 26/04/24 | 2.65 | +1.92% | 886,017 |
Delayed Quote Nasdaq, May 02, 2024 at 09:00 pm
More quotes
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.42
AUD
Average target price
0.978
AUD
Spread / Average Target
+132.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.28% | 48.09B | |
| -3.99% | 40.43B | |
| +46.96% | 40.62B | |
| -6.20% | 28.36B | |
| +6.36% | 24.89B | |
| -21.47% | 19.01B | |
| +27.58% | 12.09B | |
| -2.75% | 11.8B | |
| -2.02% | 11.88B |
- Stock Market
- Equities
- IMM Stock
- IMMP Stock
